ArticleNature2021
Rational design of a new antibiotic class for drug-resistant infections.
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 137 citations in OpenAlex.
- Drug-likeness prioritised selection identifies anti-Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Integrated in Vitro and in Silico Investigation of Antimicrobial, Anti-biofilm, and Quorum-Sensing Inhibitory Activities of Allium atroviolaceum Bulb Extract.Applied biochemistry and biotechnology · 2026Article
- Unraveling competitive protein interactions: A critical step toward improved production and therapeutics.Journal of advanced research · 2026Review
- Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules.Chemical Society reviews · 2026Review
- Reprogrammed SimCells for antimicrobial therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Mechanism and Molecular Design Principles of Cationic Surfactants: From Charge-Driven Membrane Interactions to Next-Generation Quaternary Ammonium Compounds.ChemMedChem · 2026Review
- Advances and applications of engineered protein therapeutics and their role in precision medicine.Frontiers in bioengineering and biotechnology · 2026Review
- Peptide-Based Strategies AgainstPharmaceuticals (Basel, Switzerland) · 2025Review
- Navigating the complexities of drug development for metallo-β-lactamase inhibitors.RSC medicinal chemistry · 2025Review
- Global health perspectives on antibacterial drug discovery and the preclinical pipeline.Nature reviews. Microbiology · 2025Review
- Discovery and chemical optimisation of a potent, Bi-cyclic antimicrobial inhibitor of Escherichia coli PBP3.Communications biology · 2025Article
- Modular Synthesis of Dendritic Oligo-Glycerol Cationic Surfactants for Enhanced Antibacterial Efficacy.Angewandte Chemie (International ed. in English) · 2025Article
- Novel Antibacterial Approaches and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Single-Atom Cu Anchored on Carbon Nitride as a Bifunctional Glucose Oxidase and Peroxidase Nanozyme for Antibacterial Therapy.ACS nano · 2025Article
- Recent advances and challenges in metal-based antimicrobial materials: a review of strategies to combat antibiotic resistance.Journal of nanobiotechnology · 2025Review
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- A comprehensive insight into naphthalimides as novel structural skeleton of multitargeting promising antibiotics.Future medicinal chemistry · 2025Review
- Review
- Synthesis and biological activity evaluation of a novel pleuromutilin derivative 22-((2-methyl-1-(1H-pyrrole-2-carboxamido)propan-2-yl)thio)-deoxypleuromutilin.Frontiers in pharmacology · 2025Article
- Retrospective analysis of the impact of pathogen spectrum and antibiotic resistance on the treatment efficacy of respiratory tract infections from 2012 to 2022.American journal of translational research · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
26 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of new antibiotics to treat infections caused by drug-resistant Gram-negative pathogens is of paramount importance as antibiotic resistance continues to increase worldwide
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.